Optimizing Intravitreal Pharmacotherapies for Diabetic Macular Edema

This session, which was included as part of the 2023 Ophthalmology 360 Summit Series, will provide an overview of the mechanism of action, safety, and efficacy of current and emerging treatments for diabetic macular edema (DME), including anti-vascular endothelial growth factor agents and corticosteroids. Discussion will also focus on disparities in caring for patients with DME, the burden of DME and its treatments on quality of life, and strategies for improving treatment adherence, with a look at some emerging approaches that have the potential to reduce treatment burden.

Upon completion of the educational activity, participants should be able to:

• Describe the best approaches to treatment selection and ongoing management of DME
• Explain advances in the medical treatment of DME, including emerging approaches
• Discuss care disparities and strategies for improving vision-related outcomes in patients with DME

To obtain a certificate of completion, a score of 70% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your certificate. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this activity, please contact AKH Inc. at ketrea@akhcme.com